Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

The Lancet

Volumn 373, Issue 9665, 2009, Pages 746-758

  Cipriani, Andrea ^a,d   Furukawa, Toshiaki A ^b   Salanti, Georgia ^c   Geddes, John R ^d   Higgins, Julian PT ^e   Churchill, Rachel ^g   Watanabe, Norio ^b   Nakagawa, Atsuo ^h   Omori, Ichiro M ^b   McGuire, Hugh ^f   Tansella, Michele ^a   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

^h KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG INDICATION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

EID: 60849086169     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60046-5     Document Type: Article

References (151)

1. Ward S., Lloyd Jones M., Pandor A., et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11 (2007) 1-160
2. National Institute for Clinical Excellence (NICE). Depression: management of depression in primary and secondary care. London: National Institute for Clinical Excellence (2007). http://guidance.nice.org.uk/CG23 (accessed Dec 19, 2008).
3. Puech A., Montgomery S.A., Prost J.F., Solles A., and Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Intern Clin Psychopharmacol 12 (1997) 99-108
4. Smith D., Dempster C., Glanville, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180 (2002) 396-404
5. Hansen A.R., Gartlehner G., Lohr K.N., Gaynes B.N., and Carey T.S. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143 (2005) 415-426
6. Cipriani A., Barbui C., Brambilla P., Furukawa T.A., Hotopf M., and Geddes J.R. Are all antidepressants really the same? The case of fluoxetine: a systematic review. J Clin Psychiatry 67 (2006) 850-864
7. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., and Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62 (2007) 1217-1227
8. Gartlehner G., Hansen R.A., Thieda P., et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative effectiveness review no 7 (2007), Agency for Healthcare Research and Quality, Rockville, MD. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm (accessed Dec 19, 2008).
9. Nemeroff C.B., Entsuah R., Benattia I., Demitrack M., Sloan D.M., and Thase M.E. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry 63 (2008) 424-434
10. Salanti G., Higgins J.P., Ades A., and Ioannidis J.P. Evaluation of networks of randomized trials. Stat Methods Med Res 17 (2008) 279-301
11. Ades A.E., Sculpher M., Sutton A., et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 24 (2006) 1-19
12. National Institute for Clinical Excellence (NICE). Antenatal and postnatal mental health. The NICE guideline on clinical management and service guidance (2007), National Institute for Clinical Excellence, London. http://www.nice.org.uk/nicemedia/pdf/CG45fullguideline.pdf (accessed Dec 19, 2008).
13. In: Higgins J.P.T., and Green S. (Eds). Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 (2006), John Wiley & Sons, Chichester, UK In: The Cochrane Library, issue 4
14. Bauer M., Whybrow P.C., Angst J., Versiani M., and Moller H.J. World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3 (2002) 5-43
15. Guyatt G.H., Juniper E.F., Walter S.D., et al. Interpreting treatment effects in randomised trials. BMJ 316 (1998) 690-693
16. Furukawa T.A., Cipriani A., Barbui C., Brambilla P., and Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. Int Clin Psychopharm 20 (2005) 49-52
17. Cipriani A., Nosè M., and Barbui C. What is a risk ratio?. Epidemiol Psichiatr Soc 16 (2007) 20-21
18. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
19. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
20. Sterne J.A., and Davey Smith G. Sifting the evidence-what's wrong with significance tests?. BMJ 322 (2001) 226-231
21. Aberg-Wistedt A., Agren H., Ekselius L., Bengtson F., and Akerblad A.C. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharm 20 (2000) 645-652
22. Aguglia E., Casacchia M., Cassano G.B., et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression. Int Clin Psychopharm 8 (1993) 197-202
23. Akkaya C., Sivrioglu Y., Sarandol A., and Kirli S. Comparison of venlafaxine XR and reboxetine in terms of efficacy and safety in major depressive disorder. Yeni Symposium 41 (2003) 170-177
24. Allard P., Gram L., Timdahl K., Behnke K., Hanson M., and Søgaard J. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 19 (2004) 1123-1130
25. Alves C., Cachola I., and Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiatry 5 (1999) 57-63
26. Amini H., Aghayan S., Jalili S.A., Akhondzadeh S., Yahyazadeh O., and Pakravan-Nejad M. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. J Clin Pharm Ther 30 (2005) 133-138
27. Andreoli V., Caillard V., Deo R.S., Rybakowski J.K., and Versiani M. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharm 22 (2002) 393-399
28. Ansseau M., Gabriels A., Loyens J., et al. Controlled comparison of paroxetine and fluvoxamine in major depression. Hum Psychopharm 9 (1994) 329-336
29. Ansseau M., Papart P., Troisfontaines B., et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology (Berl) 114 (1994) 131-177
30. Baldwin D.S., Cooper J.A., Huusom A.K., and Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21 (2006) 159-169
31. Behnke K., Sogaard J., Martin S., et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharm 23 (2003) 358-364
32. Benkert O., Szegedi A., and Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61 (2000) 656-663
33. Benkert O., Szegedi A., Philipp M., et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol 26 (2006) 75-78
34. Bennie E.H., Mullin J.M., and Martindale J.J. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 56 (1995) 229-237
35. Berlanga C., and Flores-Ramos M. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine. J Affect Disord 95 (2006) 119-123
36. Bielski R.J., Ventura D., and Chang C.C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65 (2004) 1190-1196
37. Bougerol T., Scotto J.C., and Patris M. Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Investigation 14 (2000) 77-89
38. Boulenger J.P., Huusom A.K., Florea I., Baekdal T., and Sarchiapone M. A comparative study for the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 22 (2006) 1331-1341
39. Burke W.J., Gergel I., and Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63 (2002) 331-336
40. Chen Z.M., Zhang J.H., Li Z.W., and Zhang H.M. Venlafaxine vs imipramine, sertraline in treating depression. Chinese J New Drugs Clin Remed 20 (2001) 109-111
41. Chouinard G., Saxena B., and Belanger M.C. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 54 (1999) 39-48
42. Clayton A.H., Zajecka J., Ferguson J.M., Filipiak-Reisner J.K., Brown M.T., and Schwartz G.E. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. Int Clin Psychopharmacol 18 (2003) 151-156
43. Clayton A, Wightman D, Horrigan JP, Modell JG, Richard NE, Krishen A. A comparison of the effects on sexual functioning of bupropion XL, escitalopram and placebo in outpatients with major depression. San Diego, CA: 17th Annual US Psychiatric and Mental Health Congress, Nov 18-21, 2004. Abstract no 105.
44. Clayton A.H., Croft H., Horrigan J.P., et al. Bupropion XL compared with escitalopram: effects on sexual functioning and antidepressant efficacy in two randomized, double-blind, placebo controlled studies. J Clin Psychiatry 67 (2006) 736-746
45. Clerc G.E., Ruimy P., and Verdeau Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 9 (1994) 139-143
46. Clerc G., Assicot M., Bouchard J.M., et al. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol 16 (2001) 145-151
47. Coleman C.C., Cunningham L.A., Foster V.J., et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 11 (1999) 205-215
48. Coleman C.C., King B.R., Bolden-Watson C., et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 23 (2001) 1040-1058
49. Colonna L., Andersen H.F., and Reines E.H. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 21 (2005) 1659-1668
50. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 59 (1998) 352-357
51. Croft H., Settle Jr. E., Houser T., Batey S.R., Donahue R.M.J., and Ascher J.A. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21 (1999) 643-658
52. Dalery J., and Honig A. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison. Hum Psychopharm 18 (2003) 379-384
53. Detke M.J., Wiltse C.G., Mallinckrodt C.H., McNamara R.K., Demitrack M.A., and Bitter I. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 14 (2004) 457-470
54. De Nayer A., Geerts S., and Ruelens L. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 5 (2002) 115-120
55. De Wilde J., Spiers R., Mertens C., et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 87 (1993) 141-145
56. Diaz Martinez A., Benassinni O., and Ontiveros A. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 20 (1998) 467-476
57. Dierick M., Ravizza L., and Realini R. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in out-patients. Prog Neuropsychopharmacol Biol Psychiatry 20 (1996) 57-71
58. Eker S.S., Akkaya C., Akgoz S., Sarandol A., and Kirli S. Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder. Turk Psikiyatri Derg 16 (2005) 153-163
59. Ekselius L., von Knorring L., and Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general-practice. Int Clin Psychopharm 12 (1997) 323-331
60. Fava M., Amsterdam J.D., and Deltito J.A. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 10 (1998) 145-150
61. Fava M., Rosenbaum J.F., Hoog S.L., Tepner R.G., Kopp J.B., and Nilsson M.E. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59 (2000) 119-126
62. Fava M., Hoog S.L., Judge R.A., Kopp J.B., Nilsson M.E., and Gonzales J.S. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 22 (2002) 137-147
63. Feighner J.P., Gardner E.A., and Johnston J.A. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 52 (1991) 329-335
64. Gagiano C.A. A double blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res 4 (1993) 145-152
65. Goldstein D.J., Mallinckrodt C., Lu Y., and Demitrack M.A. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 63 (2002) 225-231
66. Goldstein D.J., Lu Y., Detke M.J., Wiltse C., Mallinckrodt C., and Demitrack M.A. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24 (2004) 389-399
67. Guelfi J.D., Ansseau M., Corruble E., et al. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol 13 (1998) 121-128
68. Guelfi J.D., Ansseau M., Timmerman L., and Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21 (2001) 425-431
69. Hackett D, Salinas E, Desmet A. Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression. Paris, France: 11th European College of Neuropsychopharmacology Congress; Oct 31, to Nov 4.
70. Haffmans P.M., Timmerman L., and Hoogduin C. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The lucifer group. Int Clin Psychopharmacol 11 (1996) 157-164
71. Hong C.J., Hu W.H., Chen C.C., Hsiao C.C., Tsai S.J., and Ruwe F.J. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 64 (2003) 921-926
72. Kasper S., de Swart H., and Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 13 (2005) 884-891
73. Kato M., Fukuda T., Wakeno M., et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53 (2006) 186-195
74. Kavoussi R.J., Segraves R.T., Hughes A.R., Ascher J.A., and Johnston J.A. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 58 (1997) 532-537
75. Khan A., Bose A., Alexopoulos G.S., Gommoll C., Li D., and Gandhi C. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig 27 (2007) 481-492
76. Khanzode S.D., Dakhale G.N., Khanzode S.S., Saoji A., and Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8 (2003) 365-370
77. Kiev A., and Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58 (1997) 146-152
78. Langworth S., Bodlund O., and Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol 26 (2006) 121-127
79. Lee M.S., Ham B.J., Kee B.S., et al. Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. Curr Med Res Opin 21 (2005) 1369-1375
80. Leinonen E., Skarstein J., Behnke K., Agren H., and Helsdingen J.T. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 14 (1999) 329-337
81. Lepola U.M., Loft H., and Reines E.H. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18 (2003) 211-217
82. Massana J., Moller H.J., Burrows G.D., and Montenegro R.M. Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 14 (1999) 73-80
83. McPartlin G.M., Reynolds A., Anderson C., and Casoy J. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry 4 (1998) 127-132
84. Mehtonen O.P., Sogaard J., Roponen P., and Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. J Clin Psychiatry 61 (2000) 95-100
85. Montgomery S.A., Huusom A.K., and Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50 (2004) 57-64
86. Moore N., Verdoux H., and Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 20 (2005) 131-137
87. Nemeroff C.B., Ninan P.T., Ballenger J., et al. Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression 3 (1995) 163-169
88. Nemeroff C.B., Thase M.E., and EPIC 014 Study Group. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 41 (2007) 351-359
89. Newhouse P., Krishnan K.R., Doraiswamy M., Richter E., and Clary C. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 61 (2000) 559-568
90. Nierenberg A.A., Greist J.H., Mallinckrodt C.H., et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 23 (2007) 401-416
91. Ontiveros A., and Garcia-Barriga C. A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression. Br J Clin Res 8 (1997) 23-32
92. Oslin D.W., Ten Have T.R., Streim J.E., et al. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 64 (2003) 875-882
93. Patris M., Bouchard J.M., Bougerol T., et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 11 (1996) 129-136
94. Perahia D.G., Wang F., Mallinckrodt C.H., Walker D.J., and Detke M.J. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 21 (2006) 367-378
95. Rapaport M., Coccaro E., Sheline Y., et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 16 (1996) 373-378
96. Rossini D., Serretti A., Franchini L., et al. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol 25 (2005) 471-475
97. Rudolph R.L., and Feiger A.D. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (xr) and fluoxetine for the treatment of depression. J Affect Disord 56 (1999) 171-181
98. Schatzberg A.F., Kremer C., Rodrigues H.E., and Murphy G.M. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 10 (2002) 541-550
99. Schatzberg A., and Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 14 (2006) 361-370
100. Schoemaker J., Gailledreau J., and Hoyberg O.J. First, randomized, double-blind comparison of mirtazapine (15-45 mg) and fluvoxamine (50-150 mg) in the treatment of depression. Int J Neuropsychopharmacol 5 suppl 1 (2002) 140
101. Sechter D., Troy S., Paternetti S., and Boyer P. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 14 (1999) 41-48
102. Sechter D., Vandel P., Weiller E., Pezous N., Cabanac F., Tournoux A., and study co-coordinators. A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord 83 (2004) 233-236
103. Shelton R.C., Haman K.L., Rapaport M.H., et al. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 67 (2006) 1674-1681
104. Silverstone P.H., and Ravindran A. Once-daily venlafaxine extended release (xr) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine xr 360 study group. J Clin Psychiatry 60 (1999) 22-28
105. Sir A., D'Souza R.F., Uguz S., et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 66 (2005) 1312-1320
106. Stahl S.M. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 48 (2000) 894-901
107. Suri R.A., Altshuler L.L., Rasgon N.L., et al. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 61 (2000) 942-946
108. Taner E., Demir E.Y., and Cosar B. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial. Adv Therapy 23 (2006) 974-987
109. Thase M.E., Clayton A.H., Haight B.R., Krishen A., and Modell J.G. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy and tolerability. J Neuropsychopharm 26 (2006) 482-488
110. Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 13 (1993) 18S-22S
111. Tylee A., Beaumont G., and Bowden M.W. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general-practice. Prim Care Psychiatry 3 (1997) 51-58
112. Tzanakaki M., Guazzelli M., and Nimatoudis I. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 15 (2000) 29-34
113. Van Moffaert M., Bartholome F., Cosyns P., De Nayer A.R., and Mertens C. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharm 10 (1995) 393-405
114. Ventura D., Armstrong E.P., Skrepnek G.H., and Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 23 (2007) 245-250
115. Versiani M., Moreno R., Ramakers-van Moorsel C.J., and Schutte A.J. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 19 (2005) 137-146
116. Wade A., Crawford G.M., Angus M., Wilson R., and Hamilton L. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 18 (2003) 133-141
117. Wade A., Gembert K., and Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 23 (2007) 1605-1614
118. Weihs K.L., Settle Jr. E.C., Batey S.R., Houser T.L., Donahue R.M., and Ascher J.A. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 61 (2000) 96-202
119. Wheatley D.P., van Moffaert M., Timmerman L., and Kremer C.M. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 59 (1998) 306-312
120. Winokur A., DeMartinis N.A., McNally D.P., Gary E.M., Cormier J.L., and Gary K.A. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 64 (2003) 1224-1229
121. Yang J.C., Kim S.W., and Yu B.H. Milnacipran versus sertraline in major depressive disorder: a double-blind randomized comparative study on the treatment effect and beta-adrenergic receptor responsiveness. Korean J Psychopharmacol 14 (2003) 387-396
122. Zanardi R., Franchini L., Gasperini M., Perez J., and Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153 (1996) 1631-1633
123. A multi-centre, randomised, double-blind, parallel-group, placebo- and active-controlled, flexible dose study evaluating the efficacy, safety and tolerability of extended-release bupropion hydrochloride (150mg-300mg once daily), extended-release venlafaxine hydrochloride (75mg-150mg once daily) and placebo in subjects with major depressive disorder. http://ctr.gsk.co.uk/Summary/bupropion/III_WXL101497.pdf (accessed Sept 30, 2008).
124. A multi-centre, randomised, double-blind, parallel-group, placebo- and active-controlled, flexible dose study evaluating the efficacy, safety and tolerability of extended-release bupropion hydrochloride (150mg-300mg once daily), extended-release venlafaxine hydrochloride (75mg-150mg once daily) and placebo in subjects with major depressive disorder. http://ctr.gsk.co.uk/Summary/bupropion/III_AK130939.pdf (accessed Sept 30, 2008).
125. A multicenter, double-blind, placebo-controlled comparison of the safety and efficacy and effects on sexual functioning of wellbutrin (bupropion HCl) sustained release (SR) and fluoxetine in outpatients with moderate to severe recurrent major depression. http://ctr.gsk.co.uk/Summary/bupropion/IV_WELL_AK1A4006.pdf (accessed Sept 30, 2008).
126. An eight-week double-blind study comparing the effects of 20 mg of paroxetine to 150 mg of Wellbutrin SR in patients with major depressive disorder. http://ctr.gsk.co.uk/Summary/bupropion/IV_AK140016.pdf (accessed Sept 30, 2008).
127. A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder. http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1043_BRL_029060_115.pdf (accessed Sept 30, 2008).
128. A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder. http://ctr.gsk.co.uk/Summary/Paroxetine/III_MY1045_BRL_PAR128.pdf (accessed Sept 30, 2008).
129. A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of major depressive disorder with anxiety. http://ctr.gsk.co.uk/Summary/Paroxetine/IV_29060_785.pdf (accessed Sept 30, 2008).
130. Paroxetine and fluoxetine effects on mood and cognitive function in depressed nondemented elderly patients. http://ctr.gsk.co.uk/Summary/Paroxetine/III_421.pdf (accessed Sept 30, 2008).
131. A double-blind comparative study comparing paroxetine b.d. (twice daily) with fluoxetine b.d. (twice daily) in geriatric patients with major depression. http://www.gsk-clinicalstudyregister.com/quicksearch-list.jsp?tab=result s&letterrange=A-F&type=Medical+Condition&item=Depression &studyType=All&popu (accessed Dec 19, 2008).
132. A double-blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability. http://ctr.gsk.co.uk/Summary/Paroxetine/II_29060_356.pdf (accessed Dec 19, 2009).
133. Duloxetine versus placebo and paroxetine in the acute treatment of major depression. http://www.clinicalstudyresults.org/ (accessed Dec 19, 2008).
134. Flexible-dose comparison the safety and efficacy of escitalopram and fluoxetine in the reatment of major depressive disorder. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_i d=scsr/SCSR_SCT-MD-16_final.pdf (accessed Sept 30, 2008).
135. Fixed-dose comparison of escitalopram combination in adult patients with major depressive disorder. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_i d=scsr/SCSR_SCT-MD-35_final.pdf (accessed Sept 30, 2008).
136. A double-blind, flexible-dose comparison of escitalopram, sertraline and placebo in the treatment of major depressive disorder. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_i d=scsr/SCSR_SCT-MD-27_final.pdf (accessed Sept 30, 2008).
137. Flexible-dose comparison of the safety and efficacy of Lu 26-054 (escitalopram), citalopram, and placebo in the treatment of major depressive disorder. http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_i d=scsr/SCSR_SCT-MD-02_final.pdf (accessed Sept 30, 2008).
138. Le Lay A., Despiegel N., François C., and Duru G. Can discrete event simulation be of use in modelling major depression?. Cost Eff Resour Alloc 4 (2006) 19
139. Zimmerman M., Posternak M.A., and Chelminski I. Symptom severity and exclusion from antidepressant efficacy trials. J Clin Psychopharmacol 22 (2002) 610-614
140. Taylor M.J., Freemantle N., Geddes J.R., and Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 63 (2006) 1217-1223
141. Huwiler-Müntener K., Jüni P., Junker C., and Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. JAMA 287 (2002) 2801-2804
142. Bekelman J.E., Li Y., and Gross C.P. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289 (2003) 454-465
143. Barbui C., Cipriani A., Brambilla P., and Hotopf M. "Wish bias" in antidepressant drug trials?. J Clin Psychopharmacol 24 (2004) 126-130
144. Schwartz R.S., Curfman G.D., Morrissey S., and Drazen J.M. Full disclosure and the funding of biomedical research. N Engl J Med 358 (2008) 1850-1851
145. Kupfer D.J., and Frank E. Placebo in clinical trials for depression: complexity and necessity. JAMA 287 (2002) 1853-1854
146. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., and Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358 (2008) 252-260
147. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., and Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5 (2008) e45
148. Kirsch I., and Moncrieff J. Clinical trials and the response rate illusion. Contemp Clin Trials 28 (2007) 348-351
149. Geddes J.R., and Cipriani A. Selective serotonin reuptake inhibitors. BMJ 329 (2004) 809-810
150. Walsh B.T., Seidman S.N., Sysko R., and Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287 (2002) 1840-1847
151. Sneed J.R., Rutherford B.R., Rindskopf D., Lane D.T., Sackeim H.A., and Roose S.P. Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry 16 (2008) 65-73